BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

Core Viewpoint - BioRestorative Therapies, Inc. has announced a registered direct offering of 678,125 shares at $1.60 per share, alongside a concurrent private placement of unregistered warrants, aiming to raise approximately $1.085 million for clinical trials and development initiatives [1][2][3] Group 1: Offering Details - The offering price for the common stock is set at $1.60 per share, with the stock closing at $1.50 on October 3, 2025 [1] - The company will issue unregistered warrants to purchase up to 508,594 shares, representing 75% warrant coverage, with an exercise price of $2.75 per share [1] - The gross proceeds from the offering are expected to be $1.085 million before expenses, with the closing anticipated around October 8, 2025 [1][2] Group 2: Use of Proceeds - The net proceeds will be utilized for clinical trials related to the lead cell therapy candidate BRTX-100, pre-clinical research for the ThermoStem Program, and development of the biocosmeceuticals platform [2] - Additional funds will support general corporate purposes and working capital [2] Group 3: Company Background - BioRestorative focuses on developing therapeutic products using adult stem cells, with key programs targeting disc/spine disease and metabolic disorders [7] - The lead candidate, BRTX-100, is designed for non-surgical treatment of lumbosacral disc disorders and is currently in Phase 2 clinical trials [8] - The company is also developing therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [9] and operates a commercial BioCosmeceutical platform [10]